SCHEMBL5003151

SCHEMBL5003151

COc1ccccc1N1CCN(c2cncc(-c3ccc(F)c(Cl)c3)n2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
USP2 O75604 1/20 0.47
NPC1 O15118 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
RAB9A P51151 2/20 0.46
KDM4E B2RXH2 2/20 0.46
TP53 P04637 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
CYP2C9 P11712 3/20 0.43
TACR3 P29371 3/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4987426 0.86 LMNA (0.57) MAPTLMNAL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL4997644 0.85 LMNA (0.56) MAPTLMNAL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL4997627 0.84 NPC1 (0.55) MAPTLMNAL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL5003013 0.82 CYP11B2 (0.60) MAPTLMNASMN1; SMN2NFKB1NFKB2
SCHEMBL4996316 0.82 LMNA (0.53) MAPTLMNAL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL5003086 0.82 CYP11B1 (0.47) CYP11B1CYP11B2
SCHEMBL4994241 0.82 LMNA (0.57) MAPTLMNAL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL4995126 0.81 DRD4 (0.59) MAPTLMNAL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL4996849 0.80 LMNA (0.53) MAPTLMNAL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL5003435 0.80 TACR3 (0.55) MAPTLMNAL3MBTL1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases AXXIMA PHARMACEUTICALS AG (DE) 2008-08-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194574-A1 Pyrazine Derivatives As Effective Compounds Against Infectious Diseases PRNP, PSEN1, PPP5C MAPT 5/4885LMNA 2743/4885L3MBTL1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.